Organ-Specific Efficacy of Postischemic Empagliflozin in Acute Stroke and Myocardial Infarction Using Preclinical Models.
Authors:Jiajun Li|||Wangde Dai|||Rashid Alavi|||Juan Carreno|||Xianghong Arakaki|||Niema M Pahlevan|||Robert A Kloner
Journal: Journal of the American Heart Association
Publication Type: Journal Article
Date: 2026
DOI: 10.1161/JAHA.125.047087
ID: 42216277
Affiliations:
Affiliations
Department of Aerospace and Mechanical Engineering University of Southern California Los Angeles CA USA.|||Cardiovascular Research Institute Huntington Medical Research Institutes Pasadena CA USA.|||Cardiovascular Research Institute Huntington Medical Research Institutes Pasadena CA USA.|||Cardiovascular Research Institute Huntington Medical Research Institutes Pasadena CA USA.|||Cardiovascular Research Institute Huntington Medical Research Institutes Pasadena CA USA.|||Department of Aerospace and Mechanical Engineering University of Southern California Los Angeles CA USA.|||Cardiovascular Research Institute Huntington Medical Research Institutes Pasadena CA USA.
Abstract
Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, has demonstrated cardioprotective and neuroprotective effects in preclinical myocardial infarction (MI) and ischemic stroke settings by reducing acute myocardial and cerebral infarction sizes. However, the optimal administration for acute protection remains unclear. Particularly, empagliflozin effects when administered after ischemia onset but before reperfusion have not been systematically evaluated for acute MI and stroke models.
